The Profit After Tax (PAT) was Rs. 76.8 crores vs Rs.44.9 crores a year ago, supported by improved margin through portfolio premiumisation, healthy mix and optimization of expenses. 

The company has recorded a robust performance with sales of Rs. 304.7 crores for the quarter ended December 31, 2022, vs Rs. 273.3 crores a year ago, up by 11%.

Procter & Gamble Health Limited announced its financial results for the second quarter ended December 31, 2022. 

The company has recorded a robust performance with sales of Rs. 304.7 crores for the quarter ended December 31, 2022, vs Rs. 273.3 crores a year ago, up by 11%. The Profit After Tax (PAT) was ₹ 76.8 crores vs Rs.44.9 crores a year ago, supported by improved margin through portfolio premiumisation, healthy mix and optimization of expenses. 

Sales for the six-month period ending December 31, 2022, are Rs. 596.6 crores, vs Rs. 541.0 crores a year ago, up by 10%. Profit After Tax for same period is ₹ 140.5 crore vs ₹ 100.2 crore a year ago up by 40%.

Milind Thatte, Managing Director, P&G Health India, said, “We delivered sales of ₹ 596.6 crores for half year, up by 10% over year ago, despite macroeconomic challenges, including rising inflation and high input costs. We have witnessed consistent growth over the second quarter and an overall promising first half of the year. Our encouraging financial results in the second quarter can be attributed to our core belief of bringing care closer to patients through innovative approaches.